Sign In
Buy ELVN
$36.03
+0.510 (+1.44%)
At Close: Jun 03, 2026
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
04:05pm, Tuesday, 09'th Apr 2024
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm
BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and developm
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
08:30am, Tuesday, 19'th Mar 2024
Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 a
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
04:05pm, Thursday, 14'th Mar 2024
Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024
Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
04:05pm, Tuesday, 27'th Feb 2024
BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation s
Enliven Therapeutics: Preclinical Company With Interesting Value Proposition
12:57pm, Friday, 18'th Aug 2023
Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has raised $165 million in a private placement to fun
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
04:05pm, Thursday, 10'th Aug 2023
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
01:41pm, Friday, 04'th Aug 2023
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
01:41pm, Friday, 04'th Aug 2023
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
04:55pm, Wednesday, 31'st May 2023
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-gener
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
12:33pm, Friday, 24'th Mar 2023
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
12:27pm, Friday, 06'th Jan 2023
Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
3 Best Penny Stocks To Buy Before November According To Insiders
10:59am, Thursday, 20'th Oct 2022
Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | Pen
New to Trading Penny Stocks? Must Knows in 2022
11:30am, Sunday, 16'th Oct 2022
Are these methods part of your penny stocks trading strategy The post New to Trading Penny Stocks? Must Knows in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c
Imara (IMRA) Stock Soars 35% on Merger Agreement
10:59am, Friday, 14'th Oct 2022
Imara (NASDAQ: IMRA ) stock is rocketing higher on Friday after the company revealed plans for a merger agreement with Enliven Therapeutics. The merger agreement will involve no cash and instead see t
